Singapore markets closed
Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,307.01 -14.40 (-0.27%) Dow
39,671.04 -201.95 (-0.51%) Nasdaq
16,801.54 -31.08 (-0.18%) Bitcoin USD
69,958.83 +116.61 (+0.17%) CMC Crypto 200
1,507.53 +4.86 (+0.32%)
Prothena Corporation plc (0PT.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 09:14AM CEST. Market open.
| Previous close | 19.60 |
| Open | 19.90 |
| Bid | 19.90 x 10000 |
| Ask | 20.20 x 10000 |
| Day's range | 19.90 - 19.90 |
| 52-week range | 18.70 - 70.50 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 1.086B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
DUBLIN, May 08, 2024--Prothena today reported financial results for the first quarter of 2024 and provided business highlights
- Business Wire
Prothena to Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024--Prothena announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
- Business Wire
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
© 2024 Yahoo. All rights reserved.